MK-2206 + erlotinib

MK-2206 + erlotinib is a combination drug regimen consisting of MK-2206, a potent allosteric inhibitor of AKT kinase, and erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. MK-2206 inhibits the AKT signaling pathway which plays a key role in cancer cell growth, survival, and metabolism. Erlotinib targets EGFR to block tumor cell proliferation. The combination aims to overcome resistance mechanisms in non-small cell lung cancer (NSCLC), particularly in patients who have progressed after prior benefit from erlotinib alone. Clinical studies demonstrated that this combination met its primary endpoint by improving disease control rate in EGFR wild-type NSCLC patients previously treated with erlotinib. The regimen showed manageable toxicity with common adverse events including rash, diarrhea, fatigue, and mucositis[1][2][3][5].

Other names

AKT inhibitor MK-2206 plus Erlotinib